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Antenatal prevention of mother to 
child transmission of HIV
Abstract
An effective perinatal mother to child transmission (PMTCT) programme will reduce perinatal acquired HIV infections.  This 
goal is within reach of the South African public health sector. Early antenatal attendance and knowledge of HIV status allows 
sufficient time to implement highly active antiretroviral therapy (HAART) or ART intervention. Both measures have been proved 
to be efficient to reduce MTCT of HIV. A transmission rate of 2% can be achieved with a dual therapy regimen in non-breast-
feeding women. Mono therapy with single dose nevirapine (sd NVP) often fails due to the once off nature of the intervention as 
opposed to ample opportunity to administer zudovudine (AZT) antenatally with dual therapy. A higher CD4 threshold to initiate 
HAART increases the window of opportunity while women are reasonably healthy. Irrespective of the maternal disease the 
newborn babies receive the same ART regimen. Women requiring HAART following pregnancy with an interval of 6 months or 
longer since NVP exposure had the same virological response as compared to NVP naïve women. Dual or mono therapy for a 
second time will be as effective as with NVP naïve women. The present day routine use of ART will reduce the risk of obstetric 
interventions.
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HIV positive children
During 2005 the global prevalence of 
HIV among children (less than 15 years) 
was 2.3 million; of these 1.8 million 
(80%) were in Sub-Saharan Africa. In 
2006 there were 580,000 children newly 
infected and 370,000 children died due 
to HIV. The vast majority of children ac-
quired HIV through vertical transmission 
from mother to child.1
During 2006 the sero-positive HIV 
prevalence amongst women attending 
antenatal clinics in the public health 
sector within South Africa was 29.1%.2 
The province with the lowest prevalence 
was the Western Cape (15.2%) and the 
highest prevalence occurred in KwaZulu 
Natal (39.1%). During 2006 the National 
Department of Health estimated that 
in South Africa only 47% of pregnant 
women in the public health sector were 
tested for HIV with an estimated range 
between the 9 provinces a mere 24 to 
close to 100%.3
The third South African AIDS Conference
At the third South African AIDS Confer-
ence it was clear that huge progress 
has been made towards increasing 
awareness of HIV/AIDS among the pub-
lic at large,4 inthat there is agreement 
amongst public, private and non-gov-
ernmental organisations representing all 
walks of life, about the disease and, in 
general, what measures are required to 
combat the pandemic. Huge progress 
has also been made in treating AIDS 
by commencing highly active antire-
troviral therapy (HAART) when required 
for stages 3 and 4 disease. The number 
of people on HAART within the public 
health sector is ever increasing. The 
230,000 people on HAART are globally 
the largest programme.
However, the number of new infections 
is increasing. The horizontally acquired 
infection is difficult to curtail. The strong 
driving forces of sexual behaviour do 
require a comprehensive approach. 
This will have to include every organisa-
tion and group, with health care workers 
being one of the many role players 
involved.  
During 2006 only 14.6% of HIV posi-
tive mothers within the public health sec-
tor in South Africa received some form 
of antiretroviral therapy (ART) to prevent 
perinatal mother to child transmission 
(PMTCT) during labour, delivery and the 
postpartum period. An effective PMTCT 
programme will impact hugely on the 
number of perinatal acquired HIV infec-
tions. This is a goal within reach of the 
South African public health sector. Key 
Priority Area 1 (Prevention) number 3.2 
of the HIV/AIDS and STI National Stra-
tegic Plan for 2007 to 2011 compiled by 
the South African National AIDS Council 
(SANAC) states5:  Scale up coverage 
and improve quality of PMTCT to reduce 
MTCT to less than 5%.
Perinatal mother to child transmis-
sion of HIV
Without any intervention the vertical 
HIV transmission from mother to child 
will be 14 to 50%. The transmission 
rate can be vastly reduced by an ef-
fective PMTCT programme. An effective 
PMTCT is a most worthwhile and cost 
effective intervention and must receive 
high priority in Sub-Saharan Africa. The 
programme should begin with pre-preg-
nancy counselling and voluntary testing 
for HIV. Knowledge of HIV status prior 
to pregnancy allows a large widow of 
opportunity during which HIV positive 
women requiring HAART could com-
mence treatment. This measure will 
improve their health and immunity and 
reduce their viral loads to undetectable 
levels. Women not requiring HAART will 
commence with ART during the ante-
natal period. HIV discordant couples 
should be referred to infertility clinics for 
artificial insemination.
Presently, pre-pregnancy counselling 
is an ideal not within our short and medi-
um term grasp. Therefore the antenatal 
period remains the most important time 
for universal counselling and voluntary 
testing for HIV. All women must be en-
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couraged to have early confirmation of 
pregnancy. With pregnancy confirmed, 
health care providers must continue 
straight away with the first antenatal or 
booking visit. Women attending ante-
natal care from early in pregnancy tend 
to have the least pregnancy complica-
tions. Gestational age is established 
accurately with ultrasound, medical 
problems and pregnancy complica-
tions are detected early and appropriate 
measures can be instituted timeously. 
In addition, early antenatal attendance 
and knowledge of HIV status also allows 
women and health care providers a suf-
ficient time window to implement HAART 
or for ART intervention. Both measures 
have been proved to be highly efficient 
in reducing MTCT of HIV.1
AN EFFECTIVE PMTCT PROGRAMME 
CONSISTS OF:
Measures taken during the first ante-
natal visit
Counsel all antenatal women about HIV 
and the PMTCT programme. This must 
be done individually in a room where 
privacy is assured. Thereafter each 
woman choosing to take part in the pro-
gramme must receive individual pre-test 
counselling. Written consent must be 
obtained from women who want to be 
tested for HIV.
A rapid HIV test can be performed 
with one of the many reliable rapid tests 
presently available (Determine®, Ora-
quick®, First Response®, etc). A nega-
tive result indicates that the patient is 
HIV negative and post test counselling 
will focus on safe sexual practices in 
order to remain negative. A second test 
6 weeks later is advisable if a woman is 
considered to be at risk of being in the 
window period, due to recent sero-con-
version.
If the rapid test is positive, the patient 
is informed thereof and the importance 
of a second test explained. In circum-
stances where a laboratory is available 
to provide the result of an ELISA test 
within 2 hours, this is the preferred test. 
However, if this is not possible the confir-
matory test can be done with a rapid test 
from another manufacturer. If this test is 
also positive, the HIV status is regarded 
as positive and post-test counselling is 
performed. The result is then noted on 
the antenatal record.
Patients that are found to be HIV 
positive must have a CD4 lymphocyte 
count performed. This can be done on 
the same blood specimen sent for RPR 
testing, blood group and haemoglobin 
determination at National Health Labo-
ratory Services (NHLS) laboratories.
The first antenatal visit includes taking 
a thorough history. The medical history 
taken from women that tested HIV posi-
tive must include questions aimed at 
an initial decision regarding the World 
Health Organisation (WHO) stage of the 
disease:
• persistent painful lymph nodes
• weight loss
• skin rashes and a chronic itchy skin
• recurrent sinusitis
•  fever and rigors extending over a 
period of more than four weeks
• painful or difficult swallowing
•  chronic coughing for more than two 
weeks
• TB treatment within the past year
• severe headache
A thorough clinical examination is also 
part of the first antenatal visit. Women 
that tested HIV positive must be care-
fully examined for:
•  enlarged lymph nodes of more than 2 
cm
• skin rashes
• signs of weight loss
•  oral ulcers and oral or pharyngeal 
thrush
•  abnormal physical finding of the re-
spiratory system
If the history and physical examination 
indicates WHO stage 3 or 4 disease, the 
patient must be referred to an antiretrovi-
ral (ARV) or infectious diseases clinic for 
assessment and further management. 
Waiting for the CD4 result will cause 
an unnecessary delay with potentially 
disastrous consequences. Early adher-
ence counselling and commencement 
with HAART will be life saving.
The second antenatal visit and subse-
quent management
The second visit is usually 2 weeks later. 
At this visit the result of the CD4 count 
is checked. A second assessment is 
required to finally stage the patient ac-
cording to the WHO clinical staging. In 
addition, counselling regarding infant 
feeding options is given.  The CD4 count 
must be noted on the antenatal record. 
Subsequent management is as follows:
CD4 count 250 cells/mm
3 or more and 
WHO stage one or two
These patients have a reasonably 
intact immune system and are gener-
ally healthy. They should receive dual 
therapy:
•  Oral zidovudine (AZT) 300 mg twice 
daily from 28 weeks and 300 mg 3 
hourly during labour
•  Oral nevirapine (NVP) 200 mg to be 
administered once labour is con-
firmed
Laboratory haemoglobin (Hb) at 26 
weeks is done if a recent laboratory Hb 
is not available. The ward Hb needs to 
be repeated 2 weeks following com-
mencement of AZT and then with 4 
weekly intervals. An Hb concentration 
of less that 8g% is a contra-indication 
for the use of AZT. HIV positive women 
with low Hb concentrations and a nor-
mochromic normocytic anaemia need 
NOT be investigated for micronutrient 
deficiency. The anaemia invariably will 
be caused by the viral infection. Often 
the anaemia will also be due to iron 
deficiency. These women will have a hy-
pochromic microcytic anaemia. “Double 
iron” therapy (2 ferrosulphate tablets 3 
times a day) and folic acid 5 mg per day 
will result in a rise in the Hb concentra-
tion, allowing AZT to be commenced.
A transmission rate of 2% can be 
achieved with this regimen in non-
breastfeeding women.6 A transmission 
rate of 1.9% was achieved in Thailand 
irrespective of the obstetric manage-
ment. This regimen will greatly improve 
the estimated 6 to 8% transmission rate 
presently achieved with a dual therapy 
protocol that commences with AZT at 
34 weeks.
CD4 count less than 250 cells/mm
3 
and WHO stage three or four
These patients do not have an intact im-
mune system and need to be carefully 
evaluated for opportunistic infections. 
They will receive:
• Co-trimoxazole two tablets per day.
•  HAART if the gestational age is more 
than 12 weeks and less than 34 
weeks.
 o  When <12 weeks with a CD4 count 
less than 50 cells/mm3 or severe 
HIV illness, commence HAART as 
soon as treatment ready.
 o  When >34 weeks dual therapy is 
provided as it will not be possible 
to assess treatment readiness and 
initiate HAART prior to delivery. 
However, if the CD4 count is less 
than 50 cells/mm3 or with severe 
HIV illness, commence HAART as 
soon as treatment ready.
The guidelines provided by the National 
and Provincial Departments of Health in 
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South Africa recommend a CD4 count of 
200 cells/mm3 or more for either single 
dose NVP or dual therapy with NVP and 
AZT as recommended above.7,8 A high-
er CD4 threshold increases the window 
of opportunity to initiate HAART while 
the patient is reasonably healthy. In 
addition, the problem of NVP resistance 
will be solved, as the interval between 
delivery and the need for HAART will be 
6 months or more in most cases as ex-
plained later.9 The use of NVP as part of 
HAART will not be associated with hepa-
titis as this complication has only been 
described in cases with a CD4 count of 
above 250 cells/mm.3,10
HAART during pregnancy
Treatment readiness must be assessed. 
Pre-treatment counselling includes:
•  Ensuring a clear understanding of 
the disease progression and benefit 
of AVR drugs. Pamphlets are of great 
help.
•  Stressing the importance of adherence 
(compliance).
•  Encouraging disclosure of status to a 
treatment support person and sexual 
partner.
•  Encouraging participation in a sup-
port group.
Baseline full blood count with a differen-
tial white cell count and alanine amino-
transferase (ALT) is done. Patients with 
AIDS will often be anaemic and AZT 
and 3TC can cause anaemia. NVP can 
cause hepatitis.
To assess compliance patients are sup-
plied with 7 days of co-trimoxazole 2 
tablets per day (the packet must to be 
brought back at the next visit) and an 
appointment is given one week later.
HAART is initiated 1 week later if pa-
tients kept their appointments, complied 
with co-trimoxazole therapy, disclosed 
their status at least to support persons 
and whose baseline blood results are 
normal. This indicates treatment readi-
ness. Further pre-treatment counselling 
includes:
•  Drug specific side effects (nausea 
and diarrhoea occur commonly)
• Re-emphasise adherence
• Drug dosing specifics
HAART is then initiated:
•  Stavudine (d4T) 40 mg (30 mg if 
weight less than 60 Kg) every 12 hours
•  Lamivudine (3TC) 150 mg every 12 hours
• NVP 200 mg per day for 2 weeks
After 2 weeks the ALT is determined and 
if it is not elevated, NVP is increased to 
200 mg every 12 hours. The ALT levels 
must be checked every 4 weeks.  
Women on HAART stay on the twice 
a day regimen throughout pregnancy, 
labour and delivery. These women will 
have non-detectable or very low viral 
loads that depend on adherence. The 
PMTCT of HIV will be very low.
Important side effects of ARV that re-
quire discussion with an ARV specialist:
• NVP – a skin rash and hepatitis
•  d4T – peripheral neuropathy, lactic 
acidosis and lipo-atrophy
•  AZT – bone marrow suppression 
(anaemia, neutropenia), myopathy 
and lactic acidosis
•  3TC – diarrhoea, pancreatitis and 
anaemia
Neonatal antiretroviral therapy
Irrespective of the maternal disease, the 
newborn babies receive the same ART 
regimen:
•  NVP syrup more than 4 hours post 
delivery and more than one hours pri-
or to discharge.  NVP must be given 
within 72 hours postpartum. The dose 
with a birth weight equal or more than 
2 Kg is 0.6 ml and with a weight less 
than 2 Kg 0.2 ml per Kg.
  If maternal NVP was taken less than 
2 hours before delivery, NVP must be 
administered to the neonate within 60 
minutes of delivery and AZT following 
the first feed.
•  AZT syrup with the first dose of NVP 
and thereafter 12 hourly for 7 days. 
The dose with a weight equal or more 
than 2 Kg is 1.2 ml and if the weight 
is less than 2 Kg 0.4 ml per Kg 12 
hourly.
  The mother must feed the infant ac-
cording to the decision reached fol-
lowing counselling during the antena-
tal period. The choice of the mother 
must be respected and reinforced to 
prevent mixed feeding.
Logic behind dual therapy
Mono therapy with sd NVP often fails due 
to the once off nature of the intervention 
as opposed to ample opportunity to ad-
minister AZT antenatally.  In addition:
•  20% of transmission occurs antena-
tally, that is not addressed with sd 
NVP.
•  The viral load is reduced at time of 
onset of labour, contributing to a low-
er intrapartum transmission rate and 
reducing the risk of NVP resistance.
Safety of ART during pregnancy
Efavirenz (EFV) presently is the only 
ARV drug known to be teratogenic and 
causes neural tube defects if used dur-
ing the first trimester of pregnancy. This 
drug is one of the first line HAART drugs. 
Women on this drug must use reliable 
contraception.  Women desiring to fall 
pregnant must have the EFV replaced 
with NVP. If on EFV and found to be 
pregnant, women less than 14 weeks 
must be changed to NVP. However, with 
a gestational age of 14 weeks or be-
yond, EFV can be continued. All women 
exposed to EFV during the first trimester 
must have a detail ultrasound scan be-
tween 18 and 22 weeks of pregnancy to 
rule out neural tube defects.
The problem of NVP resistance
A single gene mutation of HIV is required 
to develop resistance against NVP. This 
is a problem of mono therapy with NVP. 
In the HIVNET 012 study in Uganda 
(subtype A and D HIV) with single dose 
(sd) NVP, 25% of women had resistant 
strains at 4 to 6 weeks postpartum.11 
However, all viruses reverted back to 
the wild type by 12 months. In the SAINT 
study in South Africa (subtype C HIV) 
where the women received two doses 
of NVP, 67% of women had resistant 
strains at 4 to 6 weeks postpartum. By 
12 months 20% of women remained with 
resistant strains.12 Only sd NVP must be 
used with mono or dual NVP based 
regimens. The long half-life (60 hours) 
of NVP is an ideal property that obviates 
the administration of a second dose of 
NVP if inadvertently given to a woman in 
false labour. Measurable levels of NVP 
can be found in the serum of women 21 
days following sd NVP.13
The relevant question is whether 
women requiring non neocleoside 
reverse transcriptase inhibitor (EFV) 
based HAART following sd NVP expo-
sure are at a disadvantage?  Jourdain et 
al compared NVP naïve and previous sd 
NVP exposed women and found that the 
clinical and immunological responses 
did not differ.9 However, the virologic re-
sponse of women with sd NVP exposure 
was significantly less likely to maximally 
suppress after 6 months on HAART 
(RNA viral load less than 50 copies per 
ml) than those without exposure (68% vs 
38%).This is a cause of concern. How-
ever, if this group was divided in groups 
with intervals shorter than 6 months and 
6 months or longer since sd NVP expo-
sure, the virological response in the NVP 
exposed group did not differ from the 
NVP naïve group.
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Women requiring PMTCT for a sec-
ond time
Due to the national antenatal HIV preva-
lence of more than 20% since 1998, it is 
common to have women pregnant for a 
second time.2 The question then arises 
about the effectiveness of sd NVP to 
prevent transmission a second time. 
This is a pertinent question taking into 
account the problem of NVP resistance 
following sd NVP exposure. A prospec-
tive cohort study in Uganda provided 
valuable insight about the effectiveness 
of single dose NVP with a second preg-
nancy.14 In the sd NVP naïve group, the 
HIV transmission rate was 17.5% and 
in the previous sd NVP exposed group 
18.4% (p=0.92).  In women who do not 
require HAART, sd NVP can be used 
with confidence as a component of dual 
or mono therapy for PMTCT. Women 
on HAART with a second pregnancy 
require routine follow-up with viral load 
estimation to assess the efficiency of 
their treatment.
Obstetric interventions that may influ-
ence PMTCT
The knowledge of the transmission risks 
of obstetric interventions mostly dates 
back to the era prior to the routine use 
of ART during pregnancy.15 The pres-
ent day routine use of ART will reduce 
the risk of interventions as illustrated 
by a transmission rate of 1.9% that was 
achieved in a non-breastfeeding study 
population in Thailand with dual therapy 
irrespective of the obstetric manage-
ment.6
Amniocentesis
Presently this procedure is performed 
under ultrasound guidance with a 
thin needle containing a stilet.  Avoid 
inserting the needle through the pla-
centa.16 The risk of transmission could 
be lower than with a needle stick injury. 
If the woman is on HAART with a non 
detectable viral load, the risk will be 
very small.17 As amniocentesis will be 
performed early in the second trimester, 
women that will be using dual therapy 
should be covered with AZT and 3TC 
for 28 days. However, the procedure 
should only be performed if there is a 
definite indication that outweighs pos-
sible risks.
External cephalic version (ECV)
The knowledge that a foetal-maternal 
bleed could occur in 2 to 3% of cases 
during external ECV done on Rhesus 
negative women, does raise concern 
regarding transmission with ECV per-
formed on HIV positive women. How-
ever, the pressure gradient across the 
placental barrier does favour a foetal-
maternal bleed.18 Therefore, knowledge 
gained from Rhesus negative women 
cannot be extrapolated to HIV transmis-
sion. Until more knowledge is available, 
ECV for HIV positive women should be 
limited to women who may not have 
medical care readily available when 
labour commences.
Rupture of membranes during labour
The transmission rates are increased 
with ruptured membranes and the risk 
increases the longer labour continues 
with ruptured membranes. If the dura-
tion of ruptured membranes continues 
beyond four hours, the risk of trans-
mission increases significantly.19 When 
transferring the progress of labour of 
HIV positive women with intact mem-
branes from the latent phase of labour 
to the active phase on the partogram, 
their membranes must not be ruptured. 
However, progress of labour must be re-
assessed after two hours and if normal 
the membranes must be kept intact. If 
progress is slow, the membranes could 
be ruptured and progress again as-
sessed after two hours. This measure 
will allow timeous delivery within the first 
four hours of ruptured membranes.
Intrapartum interventions
Transmission rates were reported to be 
higher with forceps and vacuum deliver-
ies as well as when episiotomies were 
preformed.15 However, when ARV’s 
are used, the risk will be reduced. If 
a policy of vaginal deliveries for HIV 
positive women is followed, these 
procedures could be preformed when 
indicated, with a provision that a more 
conservative approach should always 
be favoured.
Caesarean sections (CS)
Elective CS sections have been report-
ed to reduce transmission by more than 
50%.20 The most recent meta-analysis 
resulted in an even more pronounced 
beneficial effect.  Women enrolled be-
tween 34 and 36 weeks that were deliv-
ered by elective caesarean section be-
fore labour and rupture of membranes, 
had a 66% reduction (odds ratio 0.34 
and 95% CI 0.14 – 0.8) in transmission 
rates.21 This information raised the ques-
tion as to whether transmission rates of 
women on HAART with a non-detect-
able viral load delivered by elective CS 
may be less than following vaginal birth.
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